BrightGene Bio (China) Performance
| 688166 Stock | 29.55 0.68 2.36% |
The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BrightGene Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding BrightGene Bio is expected to be smaller as well. BrightGene Bio Medical right now shows a risk of 3.72%. Please confirm BrightGene Bio Medical standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if BrightGene Bio Medical will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BrightGene Bio Medical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, BrightGene Bio is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Payout Ratio 0.2133 | Ex Dividend Date 2024-07-04 |
1 | 3 Growth Companies With High Insider Ownership Growing Revenues At 43 percent - Simply Wall St | 12/12/2024 |
| Begin Period Cash Flow | 633.4 M |
BrightGene |
BrightGene Bio Relative Risk vs. Return Landscape
If you would invest 3,060 in BrightGene Bio Medical on October 17, 2024 and sell it today you would lose (105.00) from holding BrightGene Bio Medical or give up 3.43% of portfolio value over 90 days. BrightGene Bio Medical is generating 0.0107% of daily returns and assumes 3.7205% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than BrightGene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BrightGene Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BrightGene Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BrightGene Bio Medical, and traders can use it to determine the average amount a BrightGene Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0029
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 688166 |
Estimated Market Risk
| 3.72 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BrightGene Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BrightGene Bio by adding BrightGene Bio to a well-diversified portfolio.
BrightGene Bio Fundamentals Growth
BrightGene Stock prices reflect investors' perceptions of the future prospects and financial health of BrightGene Bio, and BrightGene Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BrightGene Stock performance.
| Return On Equity | 0.06 | ||||
| Return On Asset | 0.0227 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 13.85 B | ||||
| Shares Outstanding | 422.47 M | ||||
| Price To Book | 5.18 X | ||||
| Price To Sales | 10.04 X | ||||
| Revenue | 1.18 B | ||||
| Gross Profit | 670.14 M | ||||
| EBITDA | 264.6 M | ||||
| Net Income | 200.58 M | ||||
| Total Debt | 570.9 M | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 194.77 M | ||||
| Earnings Per Share | 0.45 X | ||||
| Total Asset | 5.03 B | ||||
| Retained Earnings | 830.44 M | ||||
About BrightGene Bio Performance
By analyzing BrightGene Bio's fundamental ratios, stakeholders can gain valuable insights into BrightGene Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BrightGene Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BrightGene Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BrightGene Bio is entity of China. It is traded as Stock on SHG exchange.Things to note about BrightGene Bio Medical performance evaluation
Checking the ongoing alerts about BrightGene Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BrightGene Bio Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BrightGene Bio had very high historical volatility over the last 90 days | |
| About 39.0% of the company shares are owned by insiders or employees |
- Analyzing BrightGene Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BrightGene Bio's stock is overvalued or undervalued compared to its peers.
- Examining BrightGene Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BrightGene Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BrightGene Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BrightGene Bio's stock. These opinions can provide insight into BrightGene Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BrightGene Stock analysis
When running BrightGene Bio's price analysis, check to measure BrightGene Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrightGene Bio is operating at the current time. Most of BrightGene Bio's value examination focuses on studying past and present price action to predict the probability of BrightGene Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrightGene Bio's price. Additionally, you may evaluate how the addition of BrightGene Bio to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |